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Background: The purpose of this study was to investigate lecithin-chitosan nanoparticles as 
a topical delivery system for quercetin.
Methods: Tocopheryl propylene glycol succinate was chosen to be the surfactant for the 
nanosystem. The mean particle size of the nanoparticles was 95.3 nm, and the entrapment 
efficiency and drug loading for quercetin were 48.5% and 2.45%, respectively. Topical delivery 
in vitro and in vivo of the quercetin-loaded nanoparticles was evaluated using quercetin   propylene 
glycol solution as the control.
Results: Compared with quercetin solution, the quercetin-loaded nanoparticles showed higher 
permeation ability, and significantly increased accumulation of quercetin in the skin, especially 
in the epidermis. Microstructure observation of the skin surface after administration indicated 
that the interaction between ingredients of the nanoparticles and the skin surface markedly 
changed the morphology of the stratum corneum and disrupted the corneocyte layers, thus 
facilitating the permeation and accumulation of quercetin in skin.
Conclusion: Lecithin-chitosan nanoparticles are a promising carrier for topical delivery of 
quercetin.
Keywords: quercetin, tocopheryl polyethylene glycol succinate, lecithin, chitosan, nanoparticles, 
topical delivery
Introduction
Skin is the largest organ of the human body and is directly exposed to the environment. 
Therefore, skin often suffers oxidative stress caused by environmental factors, such as 
ultraviolet irradiation, ionizing radiation, and toxic chemicals.1 Although the skin does 
provide a certain degree of self-protection, it can be overpowered by reactive oxygen 
species, sustaining severe damage, such as lipid peroxidation, enzyme inactivation, and 
DNA breakage. Superoxide radicals and hydrogen peroxide are precursors to reactive 
oxygen species.2,3 Developing effective methods to combat reactive oxygen species 
has been a subject of intense research. Quercetin, a topical antioxidant, is known to 
have the ability to delay ultraviolet radiation-mediated oxidant injury and cell death 
by scavenging oxygen radicals, protecting lipids against peroxidation to terminate the 
chain-radical reaction, and chelating metal ions to form inert complexes that prevent 
conversion of superoxide radicals and hydrogen peroxide into hydroxyl radicals.4–8 
Quercetin has superior antioxidant potency compared with many other well known anti-
oxidant molecules, owing to the optimized number and distinctive positions of the free 
hydroxyl groups in this molecule.9,10 However, insolubility of quercetin in water hinders 
its permeation into skin, and its protection for skin is limited. Therefore,   development of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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novel nanovehicles that are capable of transporting quercetin 
across the skin to exert its bioactivity in inhibiting ultraviolet 
B-induced cutaneous oxidative stress and inflammation is of 
great significance.
Nanoparticles have considerable potential in topical 
delivery of drugs due to their distinctive properties. Because 
of their increased surface area, nanoparticles have greater 
efficiency in enhancing the permeation of drugs into skin 
than many other vehicles. Several studies have shown that 
nanosized particles tend to reside in the outer layers of the 
stratum corneum and epidermis, with negligible penetration 
into the dermis.11–13
Lecithin is a natural lipid mixture of phospholipids and 
is frequently used for the preparation of various nanosystem 
delivery vehicles, such as microemulsions, liposomes, 
micelles, and nanoparticles, and is considered to be a safe and 
biocompatible excipient.14–19 Chitosan, a polycationic polymer 
comprised mainly of glucosamine units, is a N-deacetylated 
derivative of chitin. It has been reported that chitosan has 
antioxidant20,21 and anti-inflammatory properties,22,23 as well as 
many other attractive biopharmaceutical properties, including 
biocompatibility, biodegradability, bioadhesion, penetration 
enhancement, and antimicrobial activity.24–27 This polycationic 
polymer can interact with negatively charged substances to 
form a core shell nanostructure which has been proved to be 
a promising carrier for drugs.18,19,28 Chitosan has been used 
in many topical preparations to enhance drug uptake in nasal, 
buccal, and intestinal epithelia, and skin.29–33 It has also been 
reported that lecithin-chitosan nanoparticles obtained through 
the supramolecular self-organizing interaction between 
negatively charged lecithin and positively charged chitosan 
can become strongly attached to mammalian skin, which is 
slightly negatively charged, and offers better coverage for 
topical delivery of active compounds.17–19,34
In this study, quercetin-loaded lecithin-chitosan nano-
particles containing D-α-tocopheryl polyethylene glycol 
1000 succinate (TPGS) were prepared and optimized, and 
the physicochemical properties of the nanoparticles were 
characterized. In vitro and in vivo drug distribution in the 
epidermis and dermis of mice after topical administration of 
quercetin-loaded lecithin-chitosan nanoparticles was evalu-
ated, and the effect of lecithin-chitosan nanoparticles on the 
skin surface of the mice was investigated.
Materials and methods
Materials
Quercetin was purchased from Xi’an Senmu Biological 
Technology Co Ltd (Xi’an, China). Soya lecithin was 
obtained from Shanghai Taiwei Pharmaceutical Co Ltd 
(Shanghai, China). Chitosan of purity 95% (molecular 
weight 200 kDa, 85% deacetylation) was obtained from 
Haidebei Marine Bioengineering Co Ltd (Jinan, China) and 
used without further purification. TPGS was supplied by 
Wuhan Yuancheng Co Ltd (Wuhan, China). Tween80 and 
propylene glycol were purchased from Yongda Chemical 
Reagent Co Ltd (Tianjin, China). Ethanol and methanol of 
high-pressure liquid chromatography (HPLC) grade were 
purchased from Tianjin Guangcheng Chemical Agent Co 
Ltd (Tianjin, China). Other chemicals and solvents were of 
analytical reagent grade.
Preparation of nanoparticles
Lecithin-chitosan nanoparticles were prepared according to 
an established method.18 Lecithin 5% (w/v) was dissolved 
in a 96% ethanol solution. Quercetin was then dissolved in 
the ethanol solution containing lecithin to obtain a weight 
ratio of lecithin to quercetin of 10:3. The chitosan solutions 
were prepared by dissolving 10 mg of chitosan in 50 mL of 
distilled water with 0.1% acetic acid. TPGS was subsequently 
dissolved in the chitosan solution, and then 4 mL of the 
aforementioned mixed ethanol solution was injected into 
46 mL of chitosan solution through a plastic needle tubing 
(internal diameter 0.75 mm, injection rate 2 mL/minute) 
under mechanical agitation at 1000 rpm. After stirring for half 
an hour, the pH of the nanoparticle suspension was adjusted to 
4.5 with 0.5 M sodium hydroxide solution. After the resulting 
suspension was filtered through a filter membrane (0.8 µm) to 
remove the nonincorporated drug, the prepared nanoparticle 
system was obtained. The lecithin-chitosan ratio was set at 
20:1 (w/w) in the nanoparticles.
Physicochemical characterization  
of nanoparticles
Particle size and zeta potential
The mean diameter of the quercetin-loaded nanoparticles 
was measured by photon correlation spectroscopy using a 
particle sizer (Zetasizer 3000 HAS; Malvern Instruments Ltd, 
Worcestershire, UK) at a fixed angle of 90° with a He-Ne 
laser of 633 nm at 25°C. Particle size was evaluated using 
volume distribution. The zeta potential was analyzed using a 
microscopic electrophoresis system (DXD-II; Jiangsu Optics 
Co Ltd, Jiangsu, China) at 25°C.
Morphology
The morphology of the quercetin-loaded nanoparticles 
was observed under transmission electron microscopy International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(JEM-1200EX; JEOL, Tokyo, Japan). One drop of diluted 
quercetin-loaded nanoparticle suspension was deposited on 
a film-coated copper grid and stained with one drop of 2% 
(w/v) aqueous solution of phosphotungstic acid, and then 
allowed to dry for contrast enhancement. The sample was 
then examined by transmission electron microscopy.35
Entrapment efficiency and drug loading
The prepared nanoparticles were separated from the free drug 
using a Sephadex G-50 minicolumn centrifugation technique 
for measurement of entrapment efficiency.36,37 Briefly, 
0.3 mL of the prepared nanoparticle suspension was placed 
in a Sephadex G-50 minicolumn (presaturated with empty 
nanoparticles prepared using the same composition and 
methods) and centrifuged at 1000 rpm for 1 minute, and the 
column was then washed seven times with 0.1 mL of distilled 
water. Elutes containing drug-loaded nanoparticles were 
collected and adjusted to a volume of 25 mL by ethanol, and 
the elute-ethanol solution was then vortexed for 3 minutes to 
break down the nanoparticles and dissolve the quercetin. The 
mixture was then centrifuged at 12,000 rpm for 10 minutes 
to precipitate the crystallized salt and chitosan. Thereafter, 
the amount of entrapped drug in the supernatant liquid was 
detected using an ultraviolet-visible spectrophotometer 
(Lambda 15; Perkin-Elmer, Schwerzenbach, Switzerland) 
at a wavelength of 373 nm. The entrapment efficiency and 
drug-loading of quercetin in the nanoparticles were calculated 
according to the following equations:38
  EE
W
W
100%
entrapped drug
initial drug
=×
  DL
W
W
100%
entrapped drug
NPs
=×
where Winitial drug represents the initially added amount of drug 
and Wentrapped drug represents the amount of drug entrapped 
in the nanoparticles. WNP represents the total weight of all 
components in the nanoparticles.
In vitro permeation studies
Preparation of skins
The male Kunming mice (20 ± 2 g) used in the permeation 
studies were purchased from the Experimental Animal Center 
of Shandong University. The study protocol was approved by 
the ethics committee of Shandong University. The mice were 
sacrificed and their dorsal hair was carefully removed with 
a razor. The skins were obtained from the hairless regions 
of the mice, and the subcutaneous fat and connective tissue 
were trimmed. The excised skins were washed and examined 
to ensure their integrity, and were then stored in a refrigerator 
at -20°C overnight for later use.39
In vitro study in mice
The in vitro permeation experiment was carried out using 
Franz diffusion cells with an effective diffusion area of 
3.14 cm2. The excised skin was thawed and mounted between 
the donor and receptor chamber of the Franz diffusion cell, 
with the stratum corneum side facing upwards. A quercetin-
loaded nanoparticle suspension (0.5 mL) or control solution 
with the same quercetin concentration was applied to the 
surface of the stratum corneum. The receptor chamber was 
filled with 20 mL of phosphate-buffered saline (pH 7.2) 
containing 1% Tween80 which can increase quercetin 
solubility to 155.8 µg/mL and keep a sink condition for 
quercetin penetrated through the skin. The receptor medium 
was kept at 32°C ± 0.5°C and stirred at 300 rpm throughout 
the experiment. At designated time intervals (hours 0.5, 1, 2, 
4, 6, 8, 10, 12, or 24 following application) 0.5 mL of receptor 
solution was taken out and 0.5 mL of blank medium at the 
same temperature was added into the receptor compartment 
to keep the volume constant. Acetic ether 3 mL was added 
to the sample solution and vortexed for 3 minutes, and then 
centrifuged at 4000 rpm for 10 minutes. The supernatant was 
collected and air-dried in nitrogen, and the solid obtained 
was redissolved in 250 µL of methanol, then the amount of 
quercetin in the methanol solution was analyzed by HPLC.
At hours 3, 6, 9, and 12 after application of drug-loaded 
nanoparticles and quercetin propylene glycol solution, the 
skin surfaces were thoroughly washed with distilled water to 
remove excess formulation, and were then placed above an 
aqueous bath (60°C) for 60 seconds to separate the epidermis 
and dermis according to the established method.40 After that, 
the epidermis and dermis were cut into pieces and put into a 
plastic test tube (10 mL). Physiological saline solution 1 mL 
was added to each of them, and after being   homogenized, 
extraction of quercetin from the homogenized skin tissue 
was performed using the same steps as those for the receptor 
solution described earlier. The amount of quercetin was 
analyzed by HPLC.
In vivo study in mice
All the experimental mice were housed in cages, with access 
to food and water until use. Twenty-four hours prior to the 
experiment, the dorsal hair was removed with a razor and 
the bare skins were washed with physiological solution. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Quercetin-loaded nanoparticle suspension 0.5 mL (drug 
content 0.5%, w/w) or control solution was applied to the 
dorsal surface (3.14 cm2). At hours 3, 6, 9, and 12   thereafter, 
the mice were killed by cervical dislocation, and the treated 
skin area was dissected. Further steps for skin sample 
  treatment and extraction of quercetin from skin tissues were 
performed using the same methods as those described earlier. 
The amount of quercetin in the epidermis and dermis was 
analyzed by HPLC.
effect of nanoparticles on surface of skin
The aim of the experiment was to determine the topical effect 
of quercetin-loaded nanoparticle suspension on mouse skin 
using a previously reported method.41 The nanoparticle 
suspension and quercetin propylene glycol solution were 
applied to the hairless dorsal skin of mice for 24 hours. 
The mice were then killed by cervical dislocation, and the 
treated skin area was dissected and collected in 4% formalin 
for histopathological studies. About 3–4 µm of paraffin 
tissue sections were cut and subjected to hematoxylin and 
eosin staining. Microscopic pictures were taken by Nikon 
Alphaphot-2 YS2 microscope (Tokyo, Japan).
hPLc analysis of quercetin
The samples were analyzed using an HPLC system 
(1200 series; Agilent Technologies, Palo Alto, CA) and 
an HPLC column (C18, 4.6 × 250 mm, 5 µm). The mobile 
phase was a mixture of methanol-water at a ratio of 50:50 
(v/v)   containing 3% acetic acid. The flow rate was set at 
1 mL/minute and quercetin was detected at 373 nm. Aliquots 
of 20 µL of each sample were injected into the column, and 
all operations were carried out at ambient temperature. The 
peak area correlated linearly with the quercetin concentra-
tion in the range of 1.5–150 µg/mL and the lowest detection 
limit at 0.5 µg/mL.
statistical analysis
Data are shown as means ± standard deviation (n = 5). 
  Statistical data were analyzed by the Student’s t-test at the 
level of P = 0.05.
Results and discussion
Preparation of quercetin-loaded 
nanoparticles
Injection of an alcohol solution containing lecithin into 
  chitosan aqueous solution is a well established method for the 
preparation of nanoparticles, and based on previous studies, 
nanoparticles made from lecithin and chitosan exhibited well 
rounded shapes and better stability when the weight ratio of 
lecithin to chitosan was 20:1.19,24 This ratio was adopted in 
the present study. TPGS was chosen for its known   ability 
to increase drug solubility, stabilize nanosystems,42–44 and 
improve drug absorption.45,46 The visual observation of 
  prepared quercetin-loaded nanoparticles and crude quercetin 
in water is shown in Figure 1. Crude quercetin was hardly 
dissolved in water and precipitated from the suspension in a 
short time, whereas the quercetin-loaded nanoparticle suspen-
sion showed a translucent state with visible opalescence.
Figure 2  shows  the  structure  of  quercetin,  and 
  Figure 3 shows the possible structure of nanoparticles 
  prepared in this work. According to previous studies, lecithin 
and chitosan can form perfect round nanoparticles by the 
electrostatic interaction between the polycationic chitosan 
and negatively charged lecithin, in which lecithin molecules 
form the core and chitosan molecules form the hydrophilic 
shell layer to protect the inner structure.18,19 In this study, 
the hydrophobic groups in the TPGS and lecithin molecules 
intertwine with each other to form the hydrophobic core of the 
nanoparticles. Also, the hydrophilic polyethylene glycol chain 
in the molecular structure of TPGS and the hydrophilic parts 
of the lecithin molecules might participate in the formation 
of the hydrated shell layer with chitosan. Because of the 
good lipophilicity of quercetin and the hydrated structure of 
the shell layer, quercetin should dissolve or disperse in the 
hydrophobic core, and be protected by the outer shell layer. 
However, the exact structure of quercetin-loaded nanopar-
ticles still needs further investigation. The effect of TPGS on 
entrapment efficiency and drug-loading was investigated, as 
shown in Table 1. Drug-loading was clearly influenced by the 
concentration of TPGS and increased by more than five-fold 
Figure 1 Visual observation of crude quercetin in water (A) and quercetin-loaded 
nanoparticle suspension (B).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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24.78 ± 0.05 mV , respectively. It has been reported that the 
electrostatic attraction between the most acidic phenolic 
OH groups of quercetin and the positively charged particles 
influences the charge distribution, thus causing a decrease in 
zeta potential of the whole system.48 Although the measured 
zeta potential was relatively low, the nanoparticle suspension 
still showed good stability, and there was no notable change 
in morphology or particle size of the quercetin-loaded 
nanoparticles during 2 weeks stored at 4°C. The result was 
consistent with previous reports of TPGS used as a stabilizer 
for nanoparticles.49–51
In vitro and in vivo percutaneous  
delivery study
In the in vitro percutaneous study, quercetin was barely 
detectable in the receptor cell for 12 hours after administration 
HO
OH
OH
OH
OH
O
O
Figure 2 Molecular structure of quercetin.
Lecithin
Chitosan
TPGS
Quercetin
Hydrophilic
block
Hydrophobic
block
Figure 3 schematic illustration of possible packing of quercetin-loaded nanoparticles.
Table 1 Inﬂuence of the concentration of TPGS on entrapment 
efficiency and drug-loading of nanoparticles
TPGS  
(%, w/v)
Lecithin  
(%, w/v)
Chitosan  
(%, w/v)
EEa  
(%)
DLa  
(%)
0 0.4 0.02 ,10 ,0.5
1 0.4 0.02 45.01 ± 2.82 1.70 ± 0.11
1.5 0.4 0.02 46.30 ± 1.53 2.21 ± 0.11
2 0.4 0.02 48.47 ± 3.76 2.45 ± 0.08
2.5 0.4 0.02 51.07 ± 1.13 2.32 ± 0.15
Note: aMeans ± standard deviation (n = 3).
Abbreviations: DL, drug-loading; EE, entrapment efficiency; TPGS, D-α-tocopheryl 
polyethylene glycol 1000 succinate.
when the concentration of TPGS changed from 0% to 2% 
(w/v). However, with increasing concentrations of TPGS, 
drug-loading decreased slightly, indicating that drug-loading 
reached a maximum level when the TPGS concentration 
was 2%. Therefore, based on drug-loading, the optimized 
formulation for the nanoparticles was 0.02% chitosan, 0.4% 
lecithin, and 2% TPGS.
characterization of nanoparticles
The morphology of the nanoparticles was observed under 
transmission electron microscopy. As shown in Figure 4, 
the optimized nanoparticles were spherical. The particle 
size of both the drug-loaded nanoparticles and the blank 
nanoparticles was 95.3 nm and 168.0 nm, respectively, and 
the polydispersity index was 0.441 and 0.331. The relatively 
large values for the polydispersity index may be due to the 
small particle size fraction of formed micelles of TPGS. After 
quercetin was loaded into particles, the particle size became 
smaller. A possible reason for this was that the loaded drug 
enhanced the cohesive force of the hydrophobic interaction 
and thus caused the decrease in size.47
The zeta potential of the drug-loaded nanoparticles 
and blank nanoparticles was 10.85 ± 0.05 mV and 
Figure  4  Transmission  electron  microscopic  photograph  of  quercetin-loaded 
nanoparticles (10,000×).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of quercetin-loaded nanoparticles or quercetin control solution. 
The distribution of quercetin in the excised dorsal skins of 
mice is shown in Figure 5. Compared with the quercetin 
propylene glycol solution, nanoparticles could markedly 
enhance the cumulative amounts of quercetin in the dermis 
and epidermis within 12 hours of application (P , 0.05), 
and the amounts of quercetin in epidermis and dermis were 
9.00 ± 0.40 µg and 3.31 ± 0.51 µg, respectively, which were 
1.45 and 1.32 times these of the control formulation.
In vivo, quercetin extracted from the epidermis and dermis 
was analyzed by HPLC at every sampling point.   Figure 6 shows 
the amounts of quercetin remaining in the epidermis and der-
mis at hours 3, 6, 9, and 12 after application of the nanoparticle 
and control formulations. For the nanoparticles, the amounts 
of quercetin in the epidermis and dermis were 8.4 ± 1.53 µg 
and 2.21 ± 0.01 µg, respectively, which were 2.3 and 1.2 times 
those of the control formulation. The permeation behavior of 
quercetin in vivo was similar to that in vitro (P , 0.05).
The statistical difference between the experimental group 
and the control group in the accumulation of quercetin in 
the epidermis could be due to the unique characteristics of 
the prepared nanoparticles, as well as their positive charge 
and large surface area, ensuring an excellent contact surface 
between the vehicles and skin over the entire application area 
and promoting permeation and accumulation of drug in the 
skin.11,42 In addition, the nanoparticles tended to suppress 
penetration (transdermal delivery) through the skin while 
enhancing permeation (dermal delivery) of the drug into the 
upper skin layers.12,13,41,52–54 In Figure 6, the amounts of querce-
tin in the dermis were similar in the control and experimental 
groups but were clearly different in the epidermis. Because 
of the highly lipophilic properties of lecithin and quercetin, 
the carrier cannot transport the drug through the inner more 
hydrophilic skin layers. In contrast, the alcohol vehicle was 
relatively more likely to facilitate penetration of the drug into 
the dermis.55 In accordance with the experimental results, 
under the influence of multiple factors, the gap of drug 
retention between the experimental group and control group 
narrowed. Such peculiarity of lecithin-chitosan nanoparticles 
could improve accumulation of quercetin in the epidermis and 
avoid its permeation through the skin, which indicates that 
the lecithin-chitosan nanoparticles are an ideal carrier for the 
cutaneous delivery of quercetin to exert its antioxidant and 
anti-inflammatory effects in the skin. Moreover, the structure of 
lecithin-chitosan nanoparticles could influence the distribution 
of quercetin in skin tissue. A solid matrix in the core of the 
nanoparticles could immobilize quercetin molecules and show 
controlled release for quercetin, which resulted in a low con-
centration gradient, and thus quercetin stored in nanoparticles 
could hardly penetrate into the dermis and only distributed in 
the epidermis, especially in the stratum corneum.19,54
On the other hand, TPGS played a very important role in 
the formulation by disrupting the lipid structure of the stratum 
corneum to reduce the barrier of skin, and providing better 
wetting to the skin, which might be essential for bioadhesion 
and facilitating diffusion of drug through the barrier layer, 
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furthermore TPGS could also increase the diffusion coef-
ficient of the drug between the skin and the vehicle.46,56,57
To sum up, the results demonstrate that, compared with 
the control formulation, nanoparticles could significantly 
promote the accumulation of quercetin in skin, especially in 
the   epidermis. Because the efficacy of quercetin in delaying 
ultraviolet radiation-mediated oxidant injury and cell death 
mainly occurs in the epidermis, it is of great significance for 
the nanoparticles to make quercetin remain in skin, especially 
in the epidermis.
effect of nanoparticles on the surface  
of mice skin
Microscopic pictures of untreated skin, skin treated with 
quercetin propylene glycol solution, and quercetin-loaded 
nanoparticles are shown in Figure 7. Untreated skin 
(Figure 7A) had a compact stratum corneum, with the 
  corneocyte layer closely conjugated. Application of quercetin 
propylene glycol solution could slightly change the tight 
structure of the stratum corneum   (Figure 7B). The skin 
treated with the nanoparticle suspension appeared swollen, 
with increased overall thickness of the stratum corneum and, 
furthermore, loose cell junctions and increased intercellular 
space could also be observed (Figure 7C). The change in the 
skin surface resulting from the effect of the nanoparticles 
might be related to their composition. The positive charge 
of chitosan ensured close contact between the nanoparticles 
and the skin. The hydrated outer environment provided by 
chitosan and the active surface nature of TPGS provided 
better wetting to the skin, which might significantly alter the 
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barrier properties and reduce or prevent skin dehydration. 
Also, increased hydration of the stratum corneum could 
facilitate permeation of drug into the epidermis. Following 
interaction between the skin and the nanoparticles, the 
exposed lecithin could mix and fuse with lipids in the skin 
to loosen the structure of the skin and disturb the lamellar 
arrangement of the lipids to increase the thickness of the 
stratum corneum.38,58 The effects of the nanoparticles and 
their ingredients, including chitosan, TPGS, and lecithin, on 
the skin weakened the stratum corneum barrier and facilitated 
drug permeation.
Conclusion
Quercetin-loaded chitosan-lecithin nanoparticles were 
prepared in this study for topical administration. Addition of 
TPGS into the nanosystem resulted in increased entrapment 
efficiency and drug-loading of quercetin. Compared with the 
quercetin propylene glycol solution, the quercetin-loaded 
nanoparticles could notably enhance the skin permeation 
of quercetin in vitro and in vivo, and effectively promote 
the retention of quercetin in the epidermis. The interaction 
between nanoparticles and the skin surface changed 
the morphology of the stratum corneum and broke the 
close conjugation of the corneocyte layers, which resulted 
in the increased permeation of quercetin into the skin. It 
can be concluded that the obtained formulation of chitosan-
lecithin nanoparticles could be a promising vehicle for topical 
delivery of quercetin.
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